Ibitazina

Piperacillin sodium and tazobactam sodium, the active ingredient in Ibitazina, is a penicillin beta‑lactam antibiotic with beta‑lactamase inhibitor presented as an injectable solution for intravenous or intramuscular use. It treats a broad range of serious bacterial infections in hospitalized adults and immunocompromised patients.

GNH USA supplies Ibitazina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Ibitazina combines piperacillin and tazobactam to provide broad‑spectrum antibacterial coverage for several infection types.

- Intra‑abdominal infections: achieves clinical cure against polymicrobial pathogens. - Urinary tract infections: eradicates Gram‑negative and some Gram‑positive organisms. - Skin and soft tissue infections: resolves cellulitis and wound infections. - Community‑acquired and hospital‑acquired pneumonia: restores pulmonary function by eliminating causative bacteria. - Febrile neutropenia: provides rapid bacterial control in immunocompromised patients.

Adverse reactions may occur with any antimicrobial therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Rash: erythematous skin eruption. - Injection site pain: discomfort at the IV/IM site.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Clostridioides difficile‑associated diarrhea: potentially life‑threatening colitis. - Hematologic abnormalities: thrombocytopenia or neutropenia. - Renal impairment: acute kidney injury in susceptible patients.

Before initiating therapy, clinicians should evaluate patient‑specific factors.

- Renal function: adjust dose in patients with impaired clearance. - Allergy history: avoid in individuals with known penicillin hypersensitivity. - Hepatic function: monitor liver enzymes during prolonged treatment. - Concomitant antibiotics: avoid overlapping beta‑lactam agents to reduce toxicity. - Pregnancy: use only when the potential benefit justifies the potential risk. - Store at ambient temperature: keep in original container, protect from light and moisture.

Drug‑drug interactions may alter efficacy or increase toxicity.

Major Interactions (Avoid): - Probenecid: may increase piperacillin plasma concentrations. - Methotrexate: heightened risk of toxicity due to reduced clearance. - Oral contraceptives: possible reduction in hormonal efficacy. - Live vaccines: increased risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Vancomycin: additive nephrotoxic potential. - Aminoglycosides: combined renal toxicity requires monitoring. - Diuretics: may exacerbate electrolyte disturbances.